12935 Results

People

  1. Weigelt
    Weigelt
  2. Reis-Filho
    Reis-Filho
  3. Gonen
    Gonen
  4. Ladanyi
    Ladanyi
  5. Berger
    Berger
  6. Deasy
    Deasy
  7. Solit
    Solit
  8. Lewis
    Lewis
  9. Schultz
    Schultz
  10. De Stanchina
    De Stanchina

Groups

  1. Sloan Kettering Institute Postdocs (12935)
  2. GSK Faculty (6209)
  3. Department of Medicine (4655)
  4. Sloan Kettering Institute Faculty (3489)
  5. Surgery (2557)
  6. Solid Tumor Oncology Division (2525)
  7. Department of Pathology and Laboratory Medicine (2500)
  8. Center for Hematologic Malignancies (2323)
  9. Epidemiology and Biostatistics (1996)
  10. Human Oncology and Pathogenesis Program (1984)
  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (7820)
  2. Meeting Abstract (3611)
  3. Review (610)
  4. Editorial (251)
  5. Book Section (189)
  6. Conference Paper (160)
  7. Research Letter (133)
  8. Correspondence (63)
  9. Miscellaneous (62)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. Sloan Kettering Institute Postdocs (12935)
  2. GSK Faculty (6209)
  3. Department of Medicine (4655)
  4. Sloan Kettering Institute Faculty (3489)
  5. Surgery (2557)
  6. Solid Tumor Oncology Division (2525)

More Groups

People
  1. Britta Weigelt (366)
  2. Jorge Reis-Filho (327)
  3. Mithat Gonen (309)
  4. Marc Ladanyi (304)
  5. Joseph Deasy (278)
  6. Michael Berger (278)

More People

Years
  1. 2025 (393)
  2. 2024 (1038)
  3. 2023 (1151)
  4. 2022 (1364)
  5. 2021 (1176)
  6. 2020 (1240)

More Years

Publications
  1. Blood (641)
  2. Cancer Research (542)
  3. Journal of Clinical Oncology (416)
  4. Journal of Nuclear Medicine (261)
  5. Annals of Surgical Oncology (257)
  6. Clinical Cancer Research (235)

More Publications

Publishers
  1. Nature Publishing Group (1308)
  2. Elsevier Inc. (1173)
  3. American Association for Cancer Research (1039)
  4. Springer (818)
  5. Cell Press (719)
  6. American Society of Hematology (697)

More Publishers

Results (12935)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Proteolytic control and therapeutic targeting of oncogenic gene expression in acute myeloid leukemia
    Meeting Abstract

    Uni, M.; Steinberg, A. P.; Slavit, A.; Rha, S.; Cheng, S.; Schmalbrock, L. K.; Su, J.; Ma, J.; McPherson, A.; Mullighan, C. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies
    Meeting Abstract

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Developing an optimal fully-human CD371-targeting IL-18 secreting CART cell for the treatment of acute myeloid leukemia
    Meeting Abstract

    Shahid, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; Yoo, S.; Cai, W.; Pohl, M. A.; Fujino, T.; Zhang, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • TET2 and TP53 mutations cooperate in leukemia development and modulate the response to inflammation
    Meeting Abstract

    Vela, P. S.; Kelly, B.; Brady, C.; Foox, J.; Glass, J.; Levine, R. L.; Shih, A. L.
    Blood (2024)

    Fulltext@MSK | Save
  • The role of the bone marrow immune niche in preventing relapse in adult B-ALL following reduced intensity conditioning allogeneic HSCT
    Meeting Abstract

    Allen, H. E.; McIntyre, A.; Gutierrez-Abril, J.; Kirkwood, A. A.; Leongamornlert, D.; Amerikanou, R.; Cutler, E. A.; Dey, A.; Burt, R.; Chakraverty, R.; more...
    Blood (2024)

    Fulltext@MSK | Save